Business Wire

Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP

4.11.2026 17:44:00 EET | Business Wire | Press release

Share

Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/

Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP

The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November.

Most connected devices share the same weak spot: provisioning and testing on the production line. In-Factory Profile Provisioning (IFPP) addresses this challenge by enabling connectivity provisioning at scale, including in air-gapped manufacturing facilities.

With IFPP, OEMs can load the operator profile onto the eSIM at the end of their own production line, so every device leaves the factory tested, provisioned and ready to connect. Quantum-safe binding protects operator credentials throughout production, and IFPP works across all eSIM form factors.

One SKU. Every market. Today, connectivity is decided at the design stage and locked in through SIM variants, regional SKUs and separate stock. IFPP moves that decision to the very end of production. Manufacturers build one hardware platform and assign the operator profile on the line, order by order. Fewer SKUs. Less stock tied up in regional variants. Faster entry into new markets.

“With IFPP, connectivity becomes a production setting, made on the line, as late as the order allows. Multiple SIM SKUs are the next thing manufacturers get to stop managing. Sharing the same vision of manufacturing and IoT connectivity with our partners in the IFPP Early Access Program allows us to transform the IoT landscape,” said Gal Olshinka, Director, Acceleronix.

Why MFF4 needs IFPP

Compact eSIM form factors such as MFF4 are attracting growing interest from OEMs seeking to build smaller, more integrated connected devices. At just 2 x 2 mm, MFF4 is the smallest standardised eSIM, around 87% smaller than the widely used MFF2. As manufacturers explore these new form factors, provisioning flexibility becomes a key consideration.

The smallest devices, such as trackers, sensors and wearables, have the least room for error. Limited power and battery space make in-field profile downloads harder in certain use cases. IFPP addresses this need by enabling secure operator profile provisioning directly on the production line. By allowing connectivity selection later in the manufacturing process, IFPP helps OEMs adopt form factors such as MFF4 while reducing inventory complexity and supporting a common hardware platform across markets.

“As connected devices become smaller and more power-constrained, avoiding unnecessary in-field profile downloads becomes increasingly important. With IFPP, IDEMIA Secure Transactions brings its eSIM security expertise to both MNOs and device manufacturers: our quantum-safe profile management solution protects MNO credentials beyond their secure environment, while giving manufacturers greater flexibility in how they provision connected devices, across eSIM form factors,” said Philippe De Oliveira, SVP Auto/IoT Connectivity Services, IDEMIA Secure Transactions.

Built on the GSMA framework, ready today

The program follows GSMA SGP.41, the industry’s common architecture and requirements for in-factory profile provisioning. It runs on existing eSIM IoT (SGP.32) infrastructure, so OEMs can deploy now and upgrade to SGP.42 once the detailed technical specification is published.

How the partners work together

IDEMIA Secure Transactions delivers an IFPP-ready eSIM with quantum-safe profile binding and secure delivery. Acceleronix provides the IFPP Loader and factory orchestration tools that plug into existing production lines, with full traceability per device, and manages connectivity and devices once they are in the field. Orange supplies the operator profiles and managed IoT global connectivity through its own network and roaming partners, so devices join the network from first power-on.

“IFPP makes cellular connectivity simpler for our customers. The operator profile is provisioned in the factory, so the device is ready to connect from day one. That removes a real barrier for IoT manufacturers and opens cellular to many more devices and use cases. Together with IDEMIA Secure Transactions and Acceleronix, Orange is making IoT simpler to deploy, easier to scale and secure by design. The solution is already quantum safe,” said Philippe Lucas, EVP Partnerships, Content and Devices, Orange.

Availability

With Orange, the program brings together a leading global operator, a trusted eSIM security provider and an end-to-end IoT platform. IFPP trial kits are available for OEMs and device makers who want to evaluate factory provisioning with Orange profiles on their own production lines.

First live demonstration at electronica

Visitors can see IFPP live at electronica 2026, Messe München, 10 to 13 November, Hall C2, Stand 601, and sign up for an IFPP trial kit to test it on their own production line.

Book a meeting: https://www.linkedin.com/events/7521139497112342529/

About Acceleronix

Acceleronix is the end-to-end IoT partner trusted by global innovators to move faster with less complexity. From concept to global deployment, we handle design, connectivity, SIM/eSIM lifecycle, AI, cloud, and compliance so you launch faster and scale smarter. www.acceleronix.io

About IDEMIA Group

IDEMIA Group is a global technology leader with more than 10,700 employees worldwide. Its two market-leading divisions deliver mission-critical solutions that simplify and secure interactions in the physical and digital realms:

  • IDEMIA Secure Transactions (IST) is the leading technology provider making it safer and easier to pay and connect. With unmatched expertise in cryptography and credential issuance, IST is trusted by over 2000 financial institutions, mobile operators, automotive manufacturers, and IoT providers worldwide. Every day, IST secures billions of essential transactions, ensuring the highest levels of data protection and convenience.
  • IDEMIA Public Security (IPS) is a trusted provider of government-grade and secure biometric-based solutions for 600 government, state and federal agencies. With decades of experience in biometric technologies, IPS enables safer, frictionless and fairer ways to secure travel, access and citizen protection. Separately, two other government-related activities are conducted by the IDEMIA Group: civilian identity issuance in North America and road safety.

For more information, please visit www.idemia.com.

About Orange

Orange is one of the world’s leading telecommunications operators. As of the end of 2025, Orange connects 340 million customers (including MasOrange) across 26 countries and generated 40.4 billion euros in revenues. Orange is listed on the Euronext Paris (ORA).

View source version on businesswire.com: https://www.businesswire.com/news/home/20261104070181/en/

Contacts

Media contacts
Acceleronix: press@acceleronix.io
IDEMIA Secure Transactions: contact.press@idemia.com
Orange: service.presse@orange.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P

Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof

Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release

Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons

Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release

Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e

Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 15:41:00 EET | Press release

Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye